Home / Drug delivery expertise /
Sterile injectables
Kindeva supports sterile injectable programs with aseptic fill finish, tech transfer and injectable device expertise that helps programs move forward with confidence. Our Bridgeton, Missouri, facility adds a purpose-built layer to our injectable offering, shaped by decades of device innovation and complex program support.
A foundation of innovation, built to perform
Building on decades of injectable device experience, our teams support sterile injectable programs with connected expertise that helps you prepare for the critical decisions that shape a successful path from development toward supply.
Fill finish capabilities
Need dedicated sterile fill finish support? Explore how our Bridgeton facility supports vial, cartridge and prefilled syringe programs with 150M+ units of annual capacity, isolator-based filling, formulation capabilities and process controls designed to help products move from transfer to supply.
Maximizing productivity and minimizing downtime
Through strategic investments in automation, we have optimized traditionally manual processes, increasing output while reducing errors and improving efficiency. Our modular filling suites minimize downtime and provide superior scalability, ensuring your production remains on schedule.
A bridge to the future
Our Bridgeton, Missouri, facility features more than 155,000 square feet of dedicated aseptic operations space, including laboratories and formulation suites. Almost 11,000 square feet is dedicated to high-speed isolator fill suites, with four isolator filling lines supporting vial, cartridge and syringe programs.
Built with isolator-based filling, automation and sterility assurance controls, Bridgeton supports the quality and reliability your patients deserve.
From vial to value: How GLP-1s are redefining injectable care for chronic conditions
Explore how glucagon-like peptide-1 growth is reshaping injectable manufacturing and patient expectations. This whitepaper examines the shift toward prefilled syringes and autoinjectors, the capacity demands it creates, and the role of flexible fill finish infrastructure in supporting the future of chronic care.
Our fill finish capabilities
- Line speeds up to 400 units per minute for vials and 300 units per minute for cartridges and syringes
- 10 L to 500 L formulation scale to support programs from clinical development through commercial demand
- Integrated formulation and bulk handling with single-use Millipore Mobius systems
- Format-specific filling capabilities, including brim fill, volumetric filling, gas overlay, vacuum stoppering and traditional mechanical stoppering
- Built-in process controls, including integrated PUPSIT, in-process fill weight checks and statistical process control during filling
- Integrated washing, depyrogenation and siliconization for vial and cartridge filling
- Annex 1-aligned aseptic operations at the Bridgeton facility
Injectable delivery platforms: Exceptional by design
Our patented single‑ and dual‑chamber sterile injection platforms are engineered for reliability, ease of use, portability and durability, drawing on our legacy as the inventors of the autoinjector. With over 60 years of innovation spanning commercial, emergency‑use and high‑reliability applications, we apply deep device and systems expertise to ensure every platform surpasses quality expectations.
We are pioneering intradermal drug delivery, offering customized microneedle array patches tailored to your precise specifications. Our advanced systems ensure the reliable delivery of a wide range of therapeutics, including vaccines, peptides, proteins, biologics and small and large molecules, with options for both solid and liquid APIs.
Our legacy of autoinjector innovation
From the very beginning of the autoinjector’s history, we have led the way in innovating self-administered injectables. Before the autoinjector, military personnel and allergy sufferers relied on options that were difficult to use and required a complex series of steps, delaying treatment in emergencies.
2024
Next-generation autoinjectors designed for reliability, usability and patient experience.
Our next-generation platforms are built for expansion with options for single or dual chambers, liquid or dry APIs and prefilled syringes or cartridges.
2009
Created the TruJect™ platform
The TruJect™ platform introduced the next generation of easy and reliable single-chamber autoinjectors with integrated sharps protection.
2002
Invented the BinaJect® platform
The BinaJect® platform introduced an industry-leading dual-chamber option that enhanced stability for intramuscular injections by keeping drugs separated in vitro and in vivo.
1970
Invented the ComboPen® platform
The ComboPen® platform was created to deliver medical countermeasures more efficiently in the field while navigating complex regulations.
1959
Created the emergency use autoinjector
The AtroPen® was one of our first autoinjector platforms. Providing fast, reliable self-injection options in emergency situations, this platform was used by the military and then NASA in 1961 with the Project Mercury spaceflight program.
Sterile injectable resources and insights
Explore our library of resources to learn more about our sterile injectable drug delivery capabilities and expertise.
Your bridge to commercial sterile manufacturing
Sterile fill finish has changed. Annex 1 compliance and data transparency are no longer future considerations; they are the baseline. At the same time, programs are expected to move faster, scale seamlessly and maintain absolute control from the first clinical batch through commercial supply. Siloed models cannot keep up with the pace and control required […]
Learn MoreThe bridge to the future of sterile injectables
Access a sterile fill finish solution designed to help your product progress from formulation through commercial scale with greater confidence and control. Having invested over $200M in our purpose-built, Annex 1-aligned facility in Bridgeton, MO, we bring together the infrastructure, expertise and control needed to accelerate your path to market. From early development through to […]
Learn MoreThe bridge to uncompromising fill finish precision
Sterile fill finish is a sequence of tightly connected control points, where performance at each stage directly influences quality, timelines and patient safety. Bridgeton is designed to deliver control at every step of the fill finish journey. Our 155,000 sq. ft. aseptic facility combines advanced automation, gloveless isolator technology and structured process design to reduce […]
Learn MoreA bridge to the future: Our world-class Bridgeton facility
Manufacturing sterile injectables today is more complex than ever. Navigating stringent aseptic requirements, evolving regulatory expectations and the need for significant specialized investment has made the path to market increasingly challenging. A fragmented approach across development, drug substance manufacturing and fill finish remains a common industry practice that can introduce critical vulnerabilities. With every handoff, […]
Learn More
Parenteral precision: Annex 1-ready sterile fill finish by design
Parenteral precision is a blog series exploring the controls, technologies and design decisions that shape modern parenteral manufacturing. Each article looks at one capability through a practical lens: what it is, how it works, who it supports and why it matters. This first blog focuses on Annex 1-ready sterile fill finish. As the European Union […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.